QUEBEC CITY, May 8 /CNW Telbec/ - Asmacure Ltée announced today that the company has closed a Series A round of financing of 9 million $US involving Fonds Bio-Innovation and Innovatech Québec Chaudière-Appalaches from Québec City, and Domain Associates from Princeton, New Jersey. This investment will support Asmacure’s operations and R & D program through the preclinical and initial clinical development of its Lead Compound aimed at a new pharmacological approach for the treatment of asthma.
